| Literature DB >> 30927588 |
Giovanni Ribaudo1, Paolo Coghi2, Enrico Zanforlin1, Betty Yuen Kwan Law2, Yuki Yu Jun Wu2, Yu Han2, Alena Congling Qiu2, Yuan Qing Qu2, Giuseppe Zagotto3, Vincent Kam Wai Wong4.
Abstract
BACE-1 is considered to be one of the targets for prevention and treatment of Alzheimer's disease (AD). We here report a novel class of semi-synthetic derivatives of prenylated isoflavones, obtained from the derivatization of natural flavonoids from Maclura pomifera. In vitro anti-AD effect of the synthesized compounds were evaluated via human recombinant BACE-1 inhibition assay. Compound 7, 8 and 13 were found to be the most active candidates which demonstrates good correlation between the computational docking and pharmacokinetic predictions. Moreover, cytotoxic studies demonstrated that the compounds are not toxic against normal and cancer cell lines. Among these three compounds, compound 7 enhance the activity of P-glycoprotein (P-gp) on A549 cancer cells and increases the activity of P-gp ATPase with a possible role on the efflux of amyloid-β across the blood- brain barrier. In conclusion, the present findings may pave the way for the discovery of a novel class of compounds to prevent and/or treat AD.Entities:
Keywords: Alzheimer’s disease; In silico molecular docking; Isoflavones; P-gp; β-Secretase(BACE-1)
Year: 2019 PMID: 30927588 DOI: 10.1016/j.bioorg.2019.03.034
Source DB: PubMed Journal: Bioorg Chem ISSN: 0045-2068 Impact factor: 5.275